Kabi Stretches Adalimumab Presence To Nine Countries
Four Further Country Launches During Third Quarter
Having started to roll out its Idacio adalimumab biosimilar in Europe earlier this year, Fresenius Kabi is now marketing the Humira rival in nine countries.
You may also be interested in...
Fresenius Kabi has reported sales ahead by 6% in 2019, as growth in emerging markets helped to offset a subdued increase in North America. Meanwhile, the firm has pushed back financial expectations for its biosimilars by a year.
Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.
As a late entrant to the European adalimumab market, Fresenius is cooling expectations for sales of its Idacio biosimilar while it continues work on late-stage candidates pegfilgrastim and tocilizumab.